SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEA

Core Viewpoint - Biomea Fusion, Inc. is under investigation for potential securities fraud and unlawful business practices, coinciding with a significant setback in its clinical trials due to FDA intervention [1][2]. Group 1: Investigation and Legal Context - The investigation focuses on whether Biomea and its officers or directors have engaged in securities fraud or other unlawful business practices [1]. - Pomerantz LLP, a prominent law firm specializing in corporate and securities litigation, is leading the investigation on behalf of Biomea's investors [2][3]. Group 2: Clinical Trial Setback - On June 6, 2024, Biomea announced that the FDA placed a full clinical hold on its Phase I/II trials for the investigational drug BMF-219, due to concerns over drug-induced hepatotoxicity observed in earlier trial phases [2]. - The specific trials affected are COVALENT-111 and COVALENT-112, which are focused on type 2 and type 1 diabetes, respectively [2]. Group 3: Market Reaction - Following the announcement of the FDA's clinical hold, Biomea's stock price plummeted by $7.13 per share, representing a 63.27% decrease, closing at $4.14 per share on June 7, 2024 [5].